课题基金 / 基金详情

BROMODEOXYURIDINE AND RADIATION THERAPY FOR CARCINOMA OF THE CERVIX, VAGINA

BROMODEOXYURIDINE AND RADIATION THERAPY FOR CARCINOMA OF THE CERVIX, VAGINA
溴脱氧尿嘧啶和放射治疗宫颈癌、阴道癌
批准号：
6113359
负责人：
Avraham Eisbruch
金额：
$2.14万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/6113359
关键词：
bromodeoxyuridine carcinoma cervix neoplasms clinical research clinical trials combination cancer therapy drug administration rate /duration drug screening /evaluation endometrium female human subject human therapy evaluation neoplasm /cancer chemotherapy neoplasm /cancer radiation therapy neoplasm /cancer relapse /recurrence uterus neoplasms vagina neoplasms women's health

项目摘要

项目成果

Avraham Eisbruch的其他基金

相似基金

相关文献

中文摘要
翻译
临床前数据表明，给予RT和胸苷类似物 放射增敏剂在每周交替的时间表中可以允许临床上 显著的放射增敏作用而没有明显增加的毒性。 这是一项使用胸苷类似物的剂量探索试验 溴脱氧尿苷（BrdUrd）和RT用于治疗 局部晚期或复发性宫颈癌、阴道癌和 子宫内膜
英文摘要
Preclinical data has shown that administering RT and thymidine analog radiosensitizer in an alternating weekly schedule may allow clinically significant radiosensitization without markedly increased toxicity. This is a dose seeking trial of the use of the thymidine analog bromodeoxyuridine (BrdUrd) and RT for the treatment of patients with locally advanced or recurrent carcinoma of the cervix, vagina and endometrium.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
INDIVIDUALIZING IMRT TREATMENT IN BRAIN AND HEAD/NECK CA
CONCURRENT RADIATION AND GEMCITABINE FOR UNRESECTABLE HEAD AND NECK TUMORS
QUALITY OF LIFE IN HEAD AND NECK CANCER
CONCURRENT RADIATION AND GEMCITABINE FOR UNRESECTABLE HEAD AND NECK TUMORS
海外基金